When the Minnesota Timberwolves are at the forefront of the league's response to the COVID-19 pandemic, it's clear that things have changed in regards to innovation and forward-thinking within the organization.
The Wolves are partnering with the world-renowned Mayo Clinic, who was already a key strategic partner as the naming rights for the Mayo Clinic Square practice facility, to spearhead a league-wide study related to coronavirus antibodies.
We previously highlighted Dr. Robby Sikka's role in the Wolves' organizational response to the COVID-19 pandemic. Sikka is the Vice President of Basketball Performance and Technology for the Timberwolves, and it's tough to find a better time to have someone with such an extensive and well-traveled background in terms of sports medicine and all things health-related when it comes to players.